All In Biotech

Drug Trial Radar · NCT02972840

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 635 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

635

Actual

Start

Apr 5, 2017

Primary completion

Feb 15, 2027

Study completion Feb 15, 2027

Sponsor

Lead sponsor
Acerta Pharma BVAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Nov 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Conditions

  • Lymphoma, Mantle Cell

Interventions

  • AcalabrutinibDrug

    Administered orally (PO)

  • BendamustineDrug

    Administered intravenously (IV)

  • RituximabDrug

    Administered intravenously (IV)

  • PlaceboDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2Time frame: Up to 6 years

Locations

228 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Downey, California

  • Research Site

    Santa Monica, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Tallahassee, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Marietta, Georgia

  • Research Site

    Westwood, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Hackensack, New Jersey

  • Research Site

    Morristown, New Jersey

  • Research Site

    Hawthorne, New York

  • Research Site

    Lake Success, New York

  • Research Site

    Portland, Oregon

  • Research Site

    Charleston, South Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Tyler, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Fort Belvoir, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Seattle, Washington

  • Research Site

    Seattle, Washington

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Caba, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Bedford Park, Australia

  • Research Site

    Concord, Australia

Showing 40 of 228 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.